Literature DB >> 2861718

Differential response to amphetamine in schizophrenia.

Z Cesarec, A K Nyman.   

Abstract

Amphetamine added to maintenance therapy with neuroleptic drugs was accompanied by relief of complaints in 32 of 48 chronic schizophrenic patients with a long-standing incapacity for work. In 22 cases this relief was followed by increased work efficiency. These gains were lost at experimental withdrawal of amphetamine. The response to amphetamine varied with type of schizophrenic symptomatology. All current regressive symptoms meant worsening in spite of concomitant neuroleptic treatment, in accordance with the dopamine hypothesis. Non-regressive subjects displaying florid symptoms, however, benefited. Worsening, in a few cases, occurred only in the absence of neuroleptics. A few subjects with negative symptoms only, seemed totally unresponsive. These findings point at variations in sensitivity to dopaminergic stimulation in schizophrenic subjects. Worsening and improvement with amphetamine were each clearly connected with type of symptomatology only when current psychotic or florid non-regressive symptoms were exhibited. In cases with negative symptoms only, the type of response could not be reliably based on clinical data. Studies of autonomic functioning and attention were therefore performed in a sub-sample. Skin conductance level, reactivity and habituation rate were found to be lower in positive responders before amphetamine. After amphetamine there were no such differences. Attention tests showed no initial differences between groups but the performance of positive responders improved with amphetamine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861718     DOI: 10.1111/j.1600-0447.1985.tb05066.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  8 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 2.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

3.  Amphetamine and negative symptoms of schizophrenia.

Authors:  M Sanfilipo; A Wolkin; B Angrist; D P van Kammen; E Duncan; S Wieland; T B Cooper; E D Peselow; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1996-01       Impact factor: 4.530

4.  Neuroadaptations to chronic exposure to drugs of abuse: relevance to depressive symptomatology seen across psychiatric diagnostic categories.

Authors:  Athina Markou; Paul J Kenny
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 5.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

6.  Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases.

Authors:  Robert A Lasser; Bryan Dirks; Henry Nasrallah; Courtney Kirsch; Joseph Gao; Michael L Pucci; Mary A Knesevich; Jean-Pierre Lindenmayer
Journal:  Neuropsychopharmacology       Date:  2013-05-08       Impact factor: 7.853

Review 7.  Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia.

Authors:  H J Möller; H M van Praag; B Aufdembrinke; P Bailey; T R Barnes; J Beck; H Bentsen; F X Eich; L Farrow; W W Fleischhacker
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

8.  Continuous performance test impairment in a 22q11.2 microdeletion mouse model: improvement by amphetamine.

Authors:  Simon R O Nilsson; Christopher J Heath; Samir Takillah; Steve Didienne; Kim Fejgin; Vibeke Nielsen; Jacob Nielsen; Lisa M Saksida; Jean Mariani; Philippe Faure; Michael Didriksen; Trevor W Robbins; Timothy J Bussey; Adam C Mar
Journal:  Transl Psychiatry       Date:  2018-11-14       Impact factor: 6.222

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.